Trial Profile
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs Cenicriviroc (Primary)
- Indications Hepatic fibrosis; Non-alcoholic steatohepatitis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms AURORA
- Sponsors Allergan; Tobira Therapeutics
- 22 Jul 2022 This trial has been competed in Slovenia, according to European Clinical Trials Database record.
- 25 Jun 2021 This trial has been completed in Poland, according to the European Clinical Trials Database record (2015-02-09).
- 11 May 2021 This trial has been completed in Austria, according to European Clinical Trials Database.